Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The FDA has approved a new formulation of the genetically engineered version of Factor VIIa, a plasma protein essential for the clotting of blood. The new formulation allows the product to be stored at room temperature for up to two years.
Subscribe to our email newsletter
NovoSeven RT- the new formulation of NovoSeven Coagulation Factor VIIa (Recombinant) – contains sucrose and L-Methionine, which allow for storage at room temperature. This is helpful for health-care facilities with limited refrigerated space. The original formula could be stored for three years at temperatures between 36 and 46 degrees Fahrenheit.
NovoSeven RT shares the same uses as the earlier NovoSeven product. These uses include the treatment of bleeding and the prevention of surgical bleeding in patients with hemophilia A or B, who have antibodies that neutralize the action of clotting Factors VIII or IX, the treatment of bleeding and the prevention of surgical bleeding in patients with congenital Factor VII deficiency and the prevention of surgical bleeding in patients with acquired hemophilia.
NovoSeven RT and NovoSeven Coagulation Factor VIIa (Recombinant) are manufactured by Novo Nordisk, located in Denmark.
Jesse Goodman, director of the FDA’s Center for Biologics Evaluation and Research, said: “Approval of this product for room temperature storage creates greater flexibility in disease management for both patients and physicians. As with all FDA-approved products, the agency will monitor NovoSeven RT throughout its life cycle.”